Coronavirus disease 2019 (COVID-19) is now a well-established and globally lethal respiratory pandemic, affecting millions with about 10% fatality rate. Infected patients show mild to severe symptoms that may manifest as mild fever, cough, headache and nausea or they may even remain asymptomatic. World Health Organization has reported over 245,373,039 confirmed cases worldwide with 4,979,421 deaths (October 2021). There are myriads of promising approaches to pharmacologically treat the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the newly reported seventh human coronavirus, which is responsible for this pandemic. Various types of potential drugs; monoclonal antibodies, interferon therapies, peptides, small molecule drugs, oligonucleotides and vaccines are under consideration and target various structural components of the virus. A strong host immune system is a key player in combating COVID-19 along with the effective vaccines that are a game-changing tool. The focus of the review is some worth mentioning drug candidates; remdesivir, lopinavir, emetine, aloxistatin, viracept, homoharringtonine, ivermectin, favipiravir, tocilizumab, chloroquine and leronlimab against COVID-19 infections, targeting the membrane nucleocapsid, spike or envelope proteins, either currently in clinical trials or under consideration. Many drugs directly inhibit the viral infection while others trigger the immune system to fight against the virus. Furthermore, we also discussed the current covid vaccines; Pfizer, Moderna, etc. from different technical lines for immunization. Therefore, here we review how the immune system tries to manage the infection as well as vaccines and some of the potential therapeutic agents.
Copyright(c) The Authors